ALERTS: MERGERS - FRANCE - EXCLUSIVE CONTROL - CLEARANCE - COMMITMENT

Exclusive control: The French Competition Authority clears, subject to conditions, the European leader in medical biology to acquire a group in the same sector (Cerba)

KEYWORDS
Reference

Fr. Comp. Auth., Dec. 23rd, 2021, dec. n° 21-DCC-261 on the acquisition of sole control of the Labexa group by the Cerba group

*This article is an automatic translation of the original article, provided here for your convenience. Read the original article. In the last few days, the French Competition Authority has posted 11 new merger clearance decisions online, including 7 simplified decisions. We will also see decision n° 21-DCC-261 of December 23, 2021 in which the French Competition

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

This document is protected by copyright laws and international copyright treaties. Non-authorised use of this document constitutes a violation of the publisher's rights and may be punished by up to 3 years imprisonment and up to a € 300 000 fine (Art. L 335-2 Code de la Propriété Intellectuelle). Personal use of this document is authorised within the limits of Art. L 122-5 CPI and DRM protection.

PDF Version

Author

  • L’actu-concurrence (Paris)
    France 4280 contributions 984243 visits

Quotation

Alain Ronzano, Exclusive control: The French Competition Authority clears, subject to conditions, the European leader in medical biology to acquire a group in the same sector (Cerba), 23 December 2021, Concurrences N° 1-2022, Art. N° 104663, www.concurrences.com

Visites 29

All reviews